Valproate: life-saving, life-changing

Thomas, Rhys ORCID: https://orcid.org/0000-0003-2062-8623 2018. Valproate: life-saving, life-changing. Clinical Medicine 18 (S2) , s1-s8. 10.7861/clinmedicine.18-2-s1

Preview

PDF - Accepted Post-Print Version Download (504kB) | Preview

Abstract

Anti-epileptic medications, and valproate principally, are commonly prescribed teratogens. There is significant concern that we are not doing enough to educate clinicians and potential parents about the risks of valproate in pregnancy. There is clear advice from the Medicines and Healthcare products Regulatory Agency (MHRA) and the International League Against Epilepsy (ILAE) about the risks of valproate exposure in utero. Reviews and guidelines that are focussed on foetal risk however fall short in being able to fully replicate the complexity of a real clinical decision. Valproate is certainly life-changing if your child is one of the 10% with a major malformation or 30-40% with a neurodevelopmental disorder, but valproate is also potentially life-saving in the context of ensuring the best possible seizure control for some mothers with epilepsy. There are significant knowledge gaps regarding the risks to mothers who elect to take another drug, or to mother and baby if she comes off medication entirely. We also should be doing more to reduce rates of sudden unexpected death in epilepsy (SUDEP) which is recognised as a key target when evaluating all maternal deaths.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects:	R Medicine > R Medicine (General)
Publisher:	Royal College of Physicians
ISSN:	1470-2118
Date of First Compliant Deposit:	9 May 2017
Date of Acceptance:	8 May 2017
Last Modified:	17 Nov 2024 06:00
URI:	https://orca.cardiff.ac.uk/id/eprint/100430

Citation Data

Cited 14 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item